ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
October 18 2021 - 7:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced the appointment of Young T. Kwon, Ph.D.,
to its Board of Directors. Dr. Kwon is a highly accomplished
corporate executive in the life sciences and biotechnology space.
He brings over a decade of expertise in strategic advising,
corporate finance and business development transactions to ADMA’s
Board.
“Young is a recognized leader in the healthcare sector and his
deep strategic and financial experience will offer invaluable
perspectives as ADMA continues to increase revenues for its
commercial immunoglobulin (“IG”) product portfolio,” said Steven
Elms, Chairman of ADMA’s Board of Directors. “Over the course of
his career, Dr. Kwon has held a variety of C-suite leadership
positions, in which he played pivotal roles involving
multibillion-dollar mergers and acquisitions. We look forward to
Young’s expert engagement and assistance in guiding our objectives,
including the Company’s evaluation of alternative business
opportunities.”
“ADMA has established a strong foundation which has enabled the
Company to successfully penetrate the rapidly growing U.S. IG
market. I am honored to join the Board during this important phase
of the Company’s growth and offering advice and guidance on ways to
unlock unrealized value from the Company’s vertically integrated
biologics manufacturing platform. I very much look forward to
leveraging my professional experience to advance ADMA’s strategic
and financial goals and ultimately maximizing value for
shareholders,” said Dr. Kwon.
Dr. Kwon is presently an operating partner at Lightstone
Ventures (“LSV”), assisting the LSV biopharmaceutical team with
deal sourcing, due diligence, and portfolio management. Prior to
LSV, he served as Chief Financial and Business Officer at Momenta
Pharmaceuticals, a biotechnology company focused on discovering and
developing novel biologic therapeutics to treat rare
immune-mediated diseases, where he most recently led the sale of
Momenta to Johnson & Johnson for approximately $6.5 billion in
2020. At Momenta, he led all finance-related and business
development initiatives, including those pertaining to the
development efforts of M254, Momenta’s hypersialylated IG clinical
program. Prior to Momenta, Dr. Kwon was a business development
professional at Biogen, driving a variety of transactions.
Dr. Kwon received a Ph.D. in Biological Chemistry and Molecular
Pharmacology from Harvard University and a B.S. in Biology from
MIT.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT: Skyler
BloomDirector, Investor Relations and Corporate Strategy |
201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Michelle Pappanastos Senior Managing Director,
Argot Partners | 212-600-1902 | michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024